3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Colorectal Neoplasms
127
Colonic Neoplasms
71
Rectal Neoplasms
56
Neoplasm Metastasis
22
Pancreatic Neoplasms
21
Stomach Neoplasms
16
Precursor Cell Lymphoblastic Leukemia-Lymphoma
14
Leukemia
11
Carcinoma, Hepatocellular
11
Neoplasms
10
Lymphoma
10
Burkitt Lymphoma
8
Adenocarcinoma Of Esophagus
8
Cholangiocarcinoma
6
Adenocarcinoma
6
Parkinson Disease 4, Autosomal Dominant Lewy Body
5
Esophageal Neoplasms
5
Leukemia, Biphenotypic, Acute
4
Intestinal Neoplasms
4
Gastrointestinal Neoplasms
4
Esophageal Squamous Cell Carcinoma
4
Digestive System Neoplasms
4
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
3
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
3
Lymphoma, Non-Hodgkin
3
Lymphoma, Large B-Cell, Diffuse
3
Gallbladder Neoplasms
3
Biliary Tract Neoplasms
3
Rectal Diseases
2
Neurotoxicity Syndromes
2
Interventions
pasireotide
2
Octreotide
2
Everolimus
2
lutetium Lu 177 dotatate
1
lanreotide
1
amino-acid, glucose, and electrolyte solution
1
Temozolomide
1
Sunitinib
1
Receptor-Like Protein Tyrosine Phosphatases, Class 2
1
Oxaliplatin
1
Leucovorin
1
Folfox protocol
1
Fluorouracil
1
Capecitabine
1
177Lu-octreotide, DOTA(0)-Tyr(3)-
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Gastro-enteropancreatic neuroendocrine tumor
×
Leucovorin
×
Clear all
NCT04919226
2025-09-10
COMPOSE
ITM Solucin GmbH
Phase 3
Active not recruiting
259 enrolled